Printer Friendly

CAMBRIDGE NEUROSCIENCE APPOINTS TWO KEY SCIENTISTS

 CAMBRIDGE NEUROSCIENCE APPOINTS TWO KEY SCIENTISTS
 CAMBRIDGE, Mass., Dec. 13 /PRNewswire/ -- Cambridge NeuroScience,


Inc. (NASDAQ: CNSI) today announced it has appointed William F. Holt, Ph.D., to the newly established position of director of in vivo Pharmacology, and Marvin B. Hendricks, Ph.D., as the head of the Gene Expression Group.
 Dr. Holt, who holds a Ph.D. in Physiology and Biophysics from Harvard University, has 10 years experience in managing the preclinical evaluation of potential pharmaceutical products. He has served at Pfizer, Inc., as manager, Metabolic Diseases/General Pharmacology, and at SmithKline Beecham, as a senior investigator.
 Dr. Hendricks holds a Ph.D. in Biology from Johns Hopkins University, and a B.S. in Life Sciences from the Massachusetts Institute of Technology. He joins CNSI after working at Repligen Corporation, where he led the group responsible for mammalian cell expression.
 Cambridge NeuroScience is engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders in three areas: neuroprotective compounds for the treatment of acute neurological disorders such as stroke and traumatic brain injury; novel antipsychotic compounds for the treatment of mental illnesses such as schizophrenia; and growth factors for the treatment of neurodegenerative diseases such as diabetic peripheral neuropathies and amyotrophic lateral sclerosis (Lou Gehrig's disease). As a complement to its antipyschotic products, the company is developing pramiracetam as an adjunct in the treatment of severe depression.
 -0- 12/13/91
 /CONTACT: Dr. Elkan R. Gamzu, president and chief operating officer of Cambridge NeuroScience, Inc., 617-225-0600; or Marcia A. Kean of Feinstein Partners Inc., 617-577-8110, for Cambridge NeuroScience, Inc./
 (CNSI) CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU: PER


KM -- NE006 -- 2476 12/13/91 15:42 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 13, 1991
Words:289
Previous Article:CHARTER POWER SYSTEMS ANNOUNCES THIRD QUARTER INCOME RISES 22 PERCENT
Next Article:HOMEDCO ANNOUNCES RESTATED YEAR-END OPERATING RESULTS
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE NAMES CO-INVENTOR OF TAGAMET SENIOR DIRECTOR OF CHEMISTRY
CAMBRIDGE NEUROSCIENCE, INC. APPOINTS EDWARD S. CAMPANARO CLINICAL TRIALS MANAGER
ROBERT MCBURNEY PH.D., PROMOTED TO CHIEF SCIENTIFIC OFFICER, SENIOR VP RESEARCH FOR CAMBRIDGE NEUROSCIENCE, INC.
ELKAN GAMZU, PH.D. SUCCEEDS ALAN J. DALBY AS CHIEF EXECUTIVE OFFICER OF CAMBRIDGE NEUROSCIENCE; DALBY TO RETIRE AS CHAIRMAN IN MAY 1994
CAMBRIDGE NEUROSCIENCE, INC. APPOINTS FORMER MERCK RESEARCH LABORATORIES DIRECTOR AS VP, CLINICAL DEVELOPMENT
CAMBRIDGE NEUROSCIENCE NAMES NANCY AMER TO BOARD OF DIRECTORS
CAMBRIDGE NEUROSCIENCE NAMES BURKHARD BLANK, M.D. TO BOARD OF DIRECTORS
CORTEX ANNOUNCES MANAGEMENT CHANGES
CAMBRIDGE NEUROSCIENCE NAMES NEW SENIOR VP, FINANCE AND BUSINESS DEVELOPMENT, AND CFO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters